Request Demo
Last update 27 Aug 2025
Epivotide
Last update 27 Aug 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms- |
Target |
Action inhibitors |
Mechanism PIK3R3 inhibitors(phosphoinositide-3-kinase regulatory subunit 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with EpivotideCTR20242305
评价伊匹乌肽滴眼液在神经营养性角膜炎患者中安全性和有效性的随机、双盲、安慰剂平行对照的多中心Ⅱ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial to evaluate the safety and efficacy of ipiluvitide eye drops in patients with neurotrophic keratitis
CTR20232869
伊匹乌肽滴眼液治疗干眼症的随机、双盲、安慰剂平行对照、单中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, single-center clinical trial of ipilimumab eye drops in the treatment of dry eye
CTR20221386
伊匹乌肽滴鼻剂治疗常年性变应性鼻炎的随机、双盲、安慰剂平行对照、多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial of ipilimumab nasal drops in the treatment of perennial allergic rhinitis
100 Clinical Results associated with Epivotide
Login to view more data
100 Translational Medicine associated with Epivotide
Login to view more data
100 Patents (Medical) associated with Epivotide
Login to view more data
100 Deals associated with Epivotide
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neurotrophic keratitis | Phase 2 | China | 08 Aug 2024 | |
| Xerophthalmia | Phase 2 | China | 12 Sep 2023 | |
| Rhinitis, Allergic, Perennial | Phase 2 | China | 19 Sep 2022 | |
| Conjunctivitis, Allergic | Phase 2 | China | 25 Aug 2021 | |
| Acute irritant rhinitis | Phase 1 | China | 07 Dec 2019 | |
| Chronic rhinitis | Phase 1 | China | 07 Dec 2019 | |
| Sinusitis | Phase 1 | China | 07 Dec 2019 | |
| Common Cold | IND Approval | China | 10 Dec 2024 | |
| Corneal epithelial defect | IND Approval | China | 26 Nov 2024 | |
| Ocular inflammation | IND Approval | China | 18 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free